This protocol is judged by an institutional evaluation board, an unbiased group that reviews any clinical trials involving human beings. If a review will involve a Routine I drug, when the board approves the protocol as ethical, the researchers must apply for an investigational new drug (IND) variety from the FDA.Therefore, medications are sometime